- Lyra Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Lyra Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 13, 2023
- Lyra Therapeutics Inc to discuss the topline results of the BEACON study Call TranscriptSep 12, 2023
- Lyra Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Lyra Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Lyra Therapeutics Inc at Jefferies London Healthcare Conference TranscriptNov 17, 2022
- Lyra Therapeutics Inc at Stifel Healthcare Conference TranscriptNov 15, 2022
- Lyra Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 14, 2022
- Lyra Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2022
- Lyra Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Lyra Therapeutics Inc at William Blair Growth Stock Conference TranscriptJun 06, 2022
- Lyra Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q3 2021 Lyra Therapeutics Inc Earnings Call TranscriptNov 09, 2021$6.79 (-3.69%)Earnings
- Q2 2021 Lyra Therapeutics Inc Earnings Call TranscriptAug 09, 2021$6.69 (-4.02%)Earnings
- Lyra Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Lyra Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q4 2020 Lyra Therapeutics Inc Earnings Call TranscriptMar 09, 2021$14.6 (+2.17%)Earnings
- Lyra Therapeutics Inc in Maria Palasis & Strong Leadership in HealthTech TranscriptOct 08, 2020
- Q2 2020 Lyra Therapeutics Inc Earnings Call TranscriptAug 05, 2020$13.96 (+1.68%)Earnings
Lyra Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
Good day, everybody. Thank you for joining us at the Bank of America annual healthcare conference being conducted virtually this year. My name is Jason Gerberry. I'm one of the biopharma analysts at BofA. And I'm pleased to be introducing our next company presenter, Lyra Therapeutics; and CEO, Maria Palasis, who has some slides that she's going to run through. So I'm going to hand the mic over to Maria. So Maria, it's all yours.
Great, thank you, Jason. It's great to be here. Thank you for the invitation. And I am going to start on slide number 3, investment summary.
So we, now, at Lyra Therapeutics have completed three clinical studies on LYR-210. Both of the products that are in development right now are targeting Chronic Rhinosinusitis. In the US, there is 14 million patients that have CRS, and globally, it's a large problem throughout the world.
In the US, there are no FDA approved medicines to treat the indication of CRS. And in fact, the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)